Protein A immunoadsorption treatment in hematology: an overview

Area of Science:

• Immunology
• Hematology
• Biotechnology

Background:

• Staphylococcal protein A (SpA) binds immunoglobulins and circulating immune complexes (CIC).
• SpA therapy removes immunoglobulins and CICs from plasma, sparing albumin and coagulation proteins.
• Clinical trials are limited, primarily focusing on autoimmune thrombocytopenic purpura (AITP) and refractoriness to platelet transfusions (RFT).

Purpose of the Study:

• To evaluate the efficacy of SpA immunoadsorption in patients with AITP and RFT.
• To assess the impact of SpA on platelet counts, immunoglobulin levels, and clinical outcomes.
• To determine the durability of response and identify patient subgroups that benefit most.

Main Methods:

• Review of existing clinical trial data for AITP and RFT.
• Analysis of a University of Minnesota study involving 12 patients with thrombocytopenia refractory to platelet transfusion treated with SpA immunoadsorption.
• Measurement of platelet counts, CIC, platelet-directed immunoglobulin (PDIG), and clinical bleeding.

Main Results:

• In a study of 72 AITP patients, 46% achieved improved platelet counts with durable responses.
• Both responders and non-responders showed decreased CIC and PDIG, with responders reaching near-normal levels.
• In the Minnesota study, 7 of 12 patients refractory to platelet transfusion showed improved platelet counts and reduced bleeding after SpA treatment.

Conclusions:

• SpA immunoadsorption is a viable treatment for AITP and RFT, demonstrating significant improvements in platelet counts and clinical outcomes.
• The beneficial effects, particularly in spleen-intact patients, warrant further prospective studies.
• SpA therapy shows promise in managing thrombocytopenia secondary to bone marrow failure and alloimmunization.